Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2015 - 2026)
Biomarin Pharmaceutical (BMRN) posted Amortization of Deferred Charges of $6.1 million for Q1 2026, up 832.01% on a QoQ basis from $653000.0 in Q4 2025, and up 22440.74% year-over-year from N/an in Q1 2025.
Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Biomarin Pharmaceutical's Amortization of Deferred Charges history runs 12 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 22440.74% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 653.1% YoY) and the FY2025 annual result came in at $2.6 million, down 21.94% from the prior year.
- Amortization of Deferred Charges was $6.1 million for Q1 2026 at Biomarin Pharmaceutical, up from $653000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $6.1 million in Q1 2026 and bottomed at $27000.0 in Q1 2025.
- A 5-year average of $785764.7 and a median of $149000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2025 — Amortization of Deferred Charges sank 97.27% — and 2026, when it surged 22440.74%.
- Biomarin Pharmaceutical's Amortization of Deferred Charges stood at $1.0 million in 2022, then fell by 3.7% to $990000.0 in 2023, then slumped by 33.33% to $660000.0 in 2024, then slipped by 1.06% to $653000.0 in 2025, then jumped by 832.01% to $6.1 million in 2026.
- Business Quant data shows BMRN's Amortization of Deferred Charges at $6.1 million in Q1 2026, $653000.0 in Q4 2025, and $27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn |
| 10 | Biomarin Pharmaceutical | 11.69 Bn | 9.47 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.09 Mn |
| Mar 31, 2026 | 6.09 Mn |
| Dec 31, 2025 | 653,000.00 |
| Dec 31, 2025 | 653,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 660,000.00 |
| Dec 31, 2024 | 660,000.00 |
| Sep 30, 2024 | 67,000.00 |
| Sep 30, 2024 | 67,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Mar 31, 2024 | 990,000.00 |
| Mar 31, 2024 | 990,000.00 |
| Dec 31, 2023 | 990,000.00 |
| Dec 31, 2023 | 990,000.00 |